These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 21291786

  • 1. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.
    Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS.
    J Clin Lipidol; 2009 Feb; 3(1):33-8. PubMed ID: 21291786
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 3. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 4. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Am J Cardiol; 2010 May 15; 105(10):1409-12. PubMed ID: 20451686
    [Abstract] [Full Text] [Related]

  • 5. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
    Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.
    Curr Med Res Opin; 2010 Apr 15; 26(4):907-15. PubMed ID: 20156032
    [Abstract] [Full Text] [Related]

  • 6. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
    Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
    J Clin Lipidol; 2009 Oct 15; 3(5):332-40. PubMed ID: 21291831
    [Abstract] [Full Text] [Related]

  • 7. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Oct 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 8. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.
    J Cardiovasc Pharmacol; 2009 Sep 15; 54(3):196-203. PubMed ID: 19597368
    [Abstract] [Full Text] [Related]

  • 9. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Bays HE, Maki KC, Doyle RT, Stein E.
    Postgrad Med; 2009 Sep 15; 121(5):145-50. PubMed ID: 19820283
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D, Morgan C, Rigby RJ, Westhuyzen J.
    Am J Kidney Dis; 2002 Feb 15; 39(2):283-90. PubMed ID: 11840368
    [Abstract] [Full Text] [Related]

  • 11. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 12. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Maki KC, Lawless AL, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW.
    J Cardiovasc Pharmacol; 2011 Apr 01; 57(4):489-94. PubMed ID: 21297494
    [Abstract] [Full Text] [Related]

  • 13. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014 Apr 01; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 01; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 15. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters.
    McKenney JM, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling D, Shalwitz RA.
    J Clin Pharmacol; 2006 Jul 01; 46(7):785-91. PubMed ID: 16809804
    [Abstract] [Full Text] [Related]

  • 16. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Jul 01; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Jul 01; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 01; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J, Brun LD, Blank D, Campeau L, Crockford P, Curnew G, Dafoe W, Davignon J, Dufour R, Emery G.
    Can J Cardiol; 1993 Jun 01; 9(5):405-12. PubMed ID: 8348392
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan 01; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.